With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate

Merck's success with its HIV drug Isentress - the first and only integrase inhibitor on the market - and a recent shift in treatment guidelines that favor still greater use, are good signs for the emerging next-generation contenders in the class